Utility of XCL1 as a Prognostic Marker in Acute Lymphoblastic Leukemia

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01380587

Acronym

XCL1

Enrollment

Registered

2011-06-27

Start date

2010-11-30

Completion date

2012-09-30

Last updated

2013-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Lymphoblastic Leukemia

Keywords

ALL, XCL1, Cytokines, Prognosis

Brief summary

The purpose of the study is to determine the utility of XCL1 in the prognosis of acute lymphoblastic leukemia.

Detailed description

Each year approximately 256,000 children and adults around the world develop a form of leukemia, and 209,000 died from it. Recently, some studies have evaluated the relationship between the concentration of some cytokines and prognosis of acute lymphoblastic leukemia. XCL1 is a lymphotactin that belongs to a cytokine subfamily called C or γ with only one cysteine in the N-terminal residue. It has been found with significant expression of receptor mRNA XCL1 (XCR1) in T and B lymphocytes and related to hematological neoplasms. For these reasons, XCL1 could be a efficient marker of prognosis in patients with acute lymphoblastic leukemia.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

1 Years to No maximum

Healthy volunteers

Inclusion criteria

Patients with newly diagnosed acute lymphoblastic leukemia .

Exclusion criteria

* Patients with prior treatment with chemotherapeutic agents. * Patients treated with immunosuppressants. * Patients under 12 months old. * Patients with a diagnosis or history of autoimmune diseases. * Patients with a diagnosis or history of immunosuppressive diseases. * Patients who do not agree to sign a Letter of Informed Consent.

Design outcomes

Primary

Measure	Time frame	Description
Number of patients with poor prognosis and high levels of XCL1	3 months	Number of patients with high levels of XCL1, expression of its receptor and other cytokines.
Number of patients with poor prognosis and high levels of cytokines	3 months	Measurements obtained will be evaluated to assess the prognosis of patients and made correlations with the concentration of IL-1β, IL-2 and XCL1 as well as the relationship XCR1 XCL1 and in leukemic cells.

Countries

Mexico

Outcome results